• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women.依托孕诺酮皮下埋植剂在超重和肥胖女性中的避孕失败率。
Obstet Gynecol. 2012 Jul;120(1):21-6. doi: 10.1097/AOG.0b013e318259565a.
2
Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.依托孕烯植入剂和左炔诺孕酮宫内节育器的长期使用:超出美国食品药品监督管理局批准使用期限两年。
Am J Obstet Gynecol. 2017 Jun;216(6):586.e1-586.e6. doi: 10.1016/j.ajog.2017.01.036. Epub 2017 Jan 29.
3
Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.人工流产后避孕选择左炔诺孕酮宫内节育器、依托孕烯植入剂或醋酸甲羟孕酮长效避孕针。
Contraception. 2015 Dec;92(6):553-9. doi: 10.1016/j.contraception.2015.06.013. Epub 2015 Jun 17.
4
Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.依托孕烯释放皮下避孕植入剂长达5年的延长使用:与左炔诺孕酮释放皮下植入剂的比较。
Hum Reprod. 2016 Nov;31(11):2491-2498. doi: 10.1093/humrep/dew222. Epub 2016 Sep 26.
5
Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial.采用短效避孕方法的女性对长效可逆避孕方法的接受度及意外妊娠情况:一项随机患者偏好试验
Am J Obstet Gynecol. 2017 Feb;216(2):101-109. doi: 10.1016/j.ajog.2016.08.033. Epub 2016 Sep 20.
6
Postpartum weight loss in overweight and obese women using the etonogestrel subdermal implant: a pilot study.超重和肥胖女性使用依托孕烯皮下植入剂进行产后体重减轻的一项试点研究。
Contraception. 2017 Jun;95(6):564-570. doi: 10.1016/j.contraception.2017.02.020. Epub 2017 Feb 24.
7
Continuation and satisfaction of reversible contraception.续用和满意可逆避孕法。
Obstet Gynecol. 2011 May;117(5):1105-1113. doi: 10.1097/AOG.0b013e31821188ad.
8
Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.药物流产时立即与延迟植入依托孕烯释放植入剂的随机对照等效性试验
Hum Reprod. 2016 Nov;31(11):2484-2490. doi: 10.1093/humrep/dew238. Epub 2016 Sep 22.
9
Quality of life of women using the etonogestrel long-acting reversible contraceptive implant after abortion for unplanned pregnancy.因意外怀孕而人工流产后使用依托孕烯长效可逆避孕植入剂的女性的生活质量。
Eur J Contracept Reprod Health Care. 2020 Aug;25(4):251-258. doi: 10.1080/13625187.2020.1760240. Epub 2020 May 21.
10
Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices.选择产后避孕植入物或胎盘娩出后宫内节育器的年轻母亲的12个月避孕持续率及再次妊娠情况
Contraception. 2016 Feb;93(2):178-83. doi: 10.1016/j.contraception.2015.10.001. Epub 2015 Oct 22.

引用本文的文献

1
Long-acting reversible contraception with etonogestrel implants in female macaques ( and ).在雌性猕猴中使用依托孕烯植入剂进行长效可逆避孕(以及)。
Front Vet Sci. 2024 Jan 8;10:1319862. doi: 10.3389/fvets.2023.1319862. eCollection 2023.
2
Pregnancy Care for Patients With Super Morbid Obesity.超级病态肥胖患者的孕期护理
Front Pediatr. 2022 Jul 19;10:839377. doi: 10.3389/fped.2022.839377. eCollection 2022.
3
Contraception During Perimenopause: Practical Guidance.围绝经期避孕:实用指南
Int J Womens Health. 2022 Jul 15;14:913-929. doi: 10.2147/IJWH.S288070. eCollection 2022.
4
What do I need to know about the etonogestrel-relesasing contraceptive implant (Nexplanon)?关于依托孕烯缓释避孕植入剂(依伴侬)我需要了解什么?
Paediatr Child Health. 2021 May 27;26(7):394-395. doi: 10.1093/pch/pxab014. eCollection 2021 Nov.
5
Contraceptive use among women through their later reproductive years: Findings from an Australian prospective cohort study.女性在生殖后期的避孕措施使用情况:来自澳大利亚前瞻性队列研究的结果。
PLoS One. 2021 Aug 11;16(8):e0255913. doi: 10.1371/journal.pone.0255913. eCollection 2021.
6
Safety and Benefits of Contraceptives Implants: A Systematic Review.避孕植入剂的安全性与益处:一项系统评价
Pharmaceuticals (Basel). 2021 Jun 8;14(6):548. doi: 10.3390/ph14060548.
7
Contraceptive Preference, Continuation Rates, and Unintended Pregnancies in Patients with Comorbidities: A Prospective Cohort Study.合并症患者的避孕偏好、续用率和意外妊娠:一项前瞻性队列研究。
J Womens Health (Larchmt). 2021 Oct;30(10):1469-1475. doi: 10.1089/jwh.2020.8536. Epub 2021 Jan 6.
8
Determinants of long acting reversible contraception utilization in Northwest Ethiopia: An institution-based case control study.埃塞俄比亚西北部长效可逆避孕措施利用的决定因素:基于机构的病例对照研究。
PLoS One. 2020 Oct 20;15(10):e0240816. doi: 10.1371/journal.pone.0240816. eCollection 2020.
9
Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya.体重指数或体重的增加似乎不会影响在肯尼亚西部的 HIV 阳性女性中基于依非韦伦的抗逆转录病毒疗法与植入物效果之间的关联。
Contraception. 2019 Oct;100(4):288-295. doi: 10.1016/j.contraception.2019.06.011. Epub 2019 Jun 24.
10
Meeting the Contraceptive Needs of a Community: Increasing Access to Long-Acting Reversible Contraception.满足社区的避孕需求:增加长效可逆避孕方法的可及性。
Mo Med. 2017 May-Jun;114(3):163-167.

本文引用的文献

1
Continuation and satisfaction of reversible contraception.续用和满意可逆避孕法。
Obstet Gynecol. 2011 May;117(5):1105-1113. doi: 10.1097/AOG.0b013e31821188ad.
2
Use of contraception in the United States: 1982-2008.美国1982 - 2008年避孕措施的使用情况
Vital Health Stat 23. 2010 Aug(29):1-44.
3
Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial.正常体重和肥胖女性在口服避孕药使用期间的卵巢抑制:一项随机对照试验。
Obstet Gynecol. 2010 Aug;116(2 Pt 1):275-283. doi: 10.1097/AOG.0b013e3181e79440.
4
Hormonal contraceptives for contraception in overweight or obese women.超重或肥胖女性避孕用激素避孕药。
Cochrane Database Syst Rev. 2010 Jul 7(7):CD008452. doi: 10.1002/14651858.CD008452.pub2.
5
The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception.避孕选择项目:减少长效可逆避孕措施的障碍。
Am J Obstet Gynecol. 2010 Aug;203(2):115.e1-7. doi: 10.1016/j.ajog.2010.04.017. Epub 2010 Jun 11.
6
Contraceptive implants.避孕植入物。
Semin Reprod Med. 2010 Mar;28(2):110-7. doi: 10.1055/s-0030-1248135. Epub 2010 Mar 29.
7
Prevalence and trends in obesity among US adults, 1999-2008.美国成年人肥胖率的流行趋势及变化,1999-2008 年。
JAMA. 2010 Jan 20;303(3):235-41. doi: 10.1001/jama.2009.2014. Epub 2010 Jan 13.
8
Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 20091.肥胖女性的避孕考虑因素:发布日期 2009 年 9 月 1 日,20091 年 SFP 指南。
Contraception. 2009 Dec;80(6):583-90. doi: 10.1016/j.contraception.2009.08.001. Epub 2009 Sep 24.
9
Factors associated with contraceptive choice and inconsistent method use, United States, 2004.2004年美国与避孕方法选择及方法使用不一致相关的因素
Perspect Sex Reprod Health. 2008 Jun;40(2):94-104. doi: 10.1363/4009408.
10
Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials.单棒式依托孕烯植入剂(依伴侬)的安全性与有效性:11项国际临床试验结果
Fertil Steril. 2009 May;91(5):1646-53. doi: 10.1016/j.fertnstert.2008.02.140. Epub 2008 Apr 18.

依托孕诺酮皮下埋植剂在超重和肥胖女性中的避孕失败率。

Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women.

机构信息

Division of Clinical Research, Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.

出版信息

Obstet Gynecol. 2012 Jul;120(1):21-6. doi: 10.1097/AOG.0b013e318259565a.

DOI:10.1097/AOG.0b013e318259565a
PMID:22678035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4043143/
Abstract

OBJECTIVE

To estimate the contraceptive failure rates of the etonogestrel subdermal contraceptive implant in overweight and obese women and compare failure rates with women of normal weight and women using intrauterine devices (IUDs).

METHODS

The Contraceptive CHOICE Project is a large prospective cohort study designed to promote the use of long-acting reversible contraceptive methods to reduce unintended pregnancies in the St Louis region. Participants are provided reversible contraception of their choice at no cost. We collected baseline height and weight of each participant. During each survey, participants were asked about missed menses and possible pregnancies. Any participant who suspected a pregnancy was asked to come in for urine pregnancy testing. Analysis includes the first 8,445 participants enrolled in CHOICE of which 1,168 chose the implant and 4,200 chose the IUD. Student's t test, χ test, and Kaplan-Meier survival curves were used to perform statistical analyses to estimate failure rates in overweight and obese women using the implant and IUDs.

RESULTS

Of the women choosing the implant, 28% were overweight and 35% were obese. Of the women who chose an IUD, 27% were overweight and 35% were obese. The 3-year cumulative failure rates for implant and IUD users were less than one per 100 women-years and did not vary by body mass index.

CONCLUSION

We found no decrease in the effectiveness of the implant in overweight or obese women. The implant may be offered as a first-line contraceptive method to any woman seeking a reversible and reliable birth control method.

摘要

目的

评估依托孕诺酮皮下埋植避孕剂在超重和肥胖女性中的避孕失败率,并将其与正常体重女性和使用宫内节育器(IUD)的女性进行比较。

方法

避孕选择项目(CHOICE)是一项大型前瞻性队列研究,旨在推广使用长效可逆避孕方法,以减少圣路易斯地区的意外怀孕。参与者可免费选择可逆避孕方法。我们收集了每位参与者的基础身高和体重。在每次调查中,参与者都会被询问是否有错过经期和可能怀孕的情况。任何怀疑怀孕的参与者都被要求进行尿液妊娠测试。分析包括 CHOICE 中前 8445 名参与者,其中 1168 名选择了植入剂,4200 名选择了 IUD。使用学生 t 检验、χ 检验和 Kaplan-Meier 生存曲线进行统计分析,以估计超重和肥胖女性使用植入剂和 IUD 的失败率。

结果

选择植入剂的女性中,28%超重,35%肥胖。选择 IUD 的女性中,27%超重,35%肥胖。植入剂和 IUD 用户的 3 年累积失败率低于每 100 名女性年 1 例,且不受体重指数影响。

结论

我们没有发现植入剂在超重或肥胖女性中的有效性降低。对于寻求可靠可逆避孕方法的任何女性,都可以提供植入剂作为一线避孕方法。